



Search Quotes c [magnifying glass icon]

Trending: Apple Tightens Its Grip on PC, Tablet Industry (4:07 PM)

Follow 22.3K Like 35k [social media icons]

Advertisement for HostGator: START A WEBSITE TODAY \$0.01 NOW GET STARTED FOR ONLY 1PENNY FOR YOUR FIRST MONTH HOSTGATOR.COM 1-866-96-GATOR

HOME / EXPERT /

Advertisement

# Is CytRx Corporation the Next Pharmacyclics?

JAMES RATZ | MORE ARTICLES  
DECEMBER 13, 2013

Page 1 of 4  
view all



Advertisement

Trade with TradeStation - Trade commission-free for 90 days. [Le More.](#)

Advertisement

Help me their bro hea  
Even 60¢ a day ca give abused a a second c  
ASF  
Make a Mont

The biggest story this week in biotechnology has been the explosion seen in shares of **CytRx Corporation** ([NASDAQ:CYTR](#)). In fact, the recent move catapults CytRx to one of the top performing biotechnology stocks of 2013, and what's really interesting is that based on the recent news, CytRx may be on the verge of altering the cancer landscape — much like **Pharmacyclics** ([NASDAQ:PCYC](#)) has done over the past couple of years.

CytRx Corporation is a development-stage biotechnology company

developing a potential replacement for doxorubicin, the current standard of care in cancer treatment. The company has developed an improved version of doxorubicin, called aldoxorubicin, which it hopes can be used to treat a variety of cancers including first-line soft tissue sarcoma, second-line soft tissue sarcoma, glioblastoma multiforme, and Kaposi's sarcoma.

### Aldoxorubicin Potential

Earlier this week, CytRx announced [results](#) from its on-going Phase 2b clinical trial that was evaluating the efficacy and safety of aldoxorubicin in patients with first-line metastatic, locally advanced, or unresectable soft tissue sarcoma. Data from the trial indicated that aldoxorubicin demonstrated between 80 and 100 percent superiority over doxorubicin in progression-free survival as a first-line therapy in advanced soft tissue sarcoma. The median progression-free survival, 6-month progression-free survival and overall response rates all significantly favor aldoxorubicin treatment over doxorubicin. Additionally, there were no serious safety issues seen in the patients.

Page 1 of 4  
[view all](#)

[+ reddit this!](#)

#### YOU MAY ALSO LIKE

- |  |   |
|--|---|
| <a href="#">1. Top Pharmaceutical</a>  | <a href="#">4. Veterinary Pharmacy</a>      |
| <a href="#">2. Pharmaceutical Jobs</a> | <a href="#">5. Local Pharmacy Directory</a> |
| <a href="#">3. Health Insurance</a>    | <a href="#">6. Online Pharmacy</a>          |

**5 Keys to Inspiring Leadership, No Matter Your Style**  
Entrepreneur

**The New Diet Pill That Has Doctors Raving**  
All Consumer Health Tips

**Don't know Spanish? See this video (Shocking)**  
Pimleur Approach

**Homeowners Are In For A Big Surprise...**  
Smart Life Weekly

**These Bitcoin Facts Just Blew Our Minds**

#### BROKER PARTNERS



#### STORIES YOU'LL LOVE



**4 Biggest Box Office Surprises in January**



**10 Cars and Trucks That Survived the Polar Vortex**



**Celebrity Deaths Highlight Stark Reality: Heroin Use Is Surging**



**3 Less-Known Ways to Contribute to a Roth IRA**



**Obama, Business, and Minimum Wage: Is It Time For a Raise?**

[MORE MOST POPULAR »](#)

Advertisement

Bitcoin - KO

**Check Out These Celebrity Bikini Bodies**

MyDailyMoment

**20 Celebrities Who Shockingly Used To Be Hot**

Answers

**Actress Has Wardrobe Malfunction So Bad You Won't Believe It (PHOTO)**

Tasty Articles

Sponsored Content by Taboola

# The Death of the PC

The days of paying for costly software upgrades are numbered. The PC will soon be obsolete. And BusinessWeek reports 70% of Americans are already using the technology that will replace it. Merrill Lynch calls it "a \$160 billion opportunity." Computing giants including IBM, Yahoo!, and Amazon are racing to be the first to cash in on this PC-killing revolution. Yet, a small group of little-known companies have a huge head start. Get the full details on these companies, and the technology that is destroying the PC, in a free video from The Motley Fool. Enter your email address below to view this stunning video.

[Click Here, It's Free!](#)

[The Motley Fool Terms And Conditions](#)

[Wall St. Cheat Sheet Privacy Policy](#)

More Articles About: [Aldoxorubicin](#) [Allianz](#) [barclays](#) [biotechnology](#)

[BlackRock](#) [California Public Employees' Retirement System](#) [cancer treatment](#)

[Capital World Investors](#) [CytRx Corporation](#) [deutsche bank](#) [doxorubicin](#)

[Goldman Sachs](#) [Healthcare](#) [Imbruvica](#) [James Ratz](#) [Janus Capital](#)

[medicine](#) [NASDAQ:CYTR](#) [Pharmacyclics](#) [shares](#) [State Street](#)

[Stocks](#) [T Rowe Price](#) [The Baker Brothers](#) [Vanguard](#)




Advertisement

To contact the reporter on this story: [staff.writers@wallstcheatsheet.com](mailto:staff.writers@wallstcheatsheet.com)

To contact the editor responsible for this story:

[editors@wallstcheatsheet.com](mailto:editors@wallstcheatsheet.com)



Add a comment...

Also post on Facebook

Posting as Tony Laguna ([Change](#))

[Comment](#)

Facebook social plugin

**Norton delivers 5 patented layers of powerful protection.**  
 Introducing the all new Norton lineup. Built to keep you safe, no matter what you do online. [FIND the RIGHT PROTECTION](#)

**Wall St. Cheat Sheet has been featured in these fine media outlets:**



[Login](#)

[Jobs](#)

[Google+](#)

[STOCK INVESTOR CHEAT SHEET](#)

[About Us](#)

[Affiliates](#)

[Facebook](#)

[GOLD & SILVER INVESTMENT NEWSLETTER](#)

[Customer Support](#)

[Archive](#)

[Twitter](#)

[COMMODITIES INVESTMENT NEWSLETTER](#)


[Contact Us](#)

[Legal Disclaimer](#)

[Linkedin](#)

[WEEKLY STOCK CHEAT SHEETS](#)

Policy

 Email

MARKET OUTLOOK 2013

© & ® 2013 Wall St. Cheat Sheet, All  
Rights Reserved

